Latest Pharmaceuticals News

Page 17 of 44
Tryptamine Therapeutics reported a $5.33 million loss for FY25 while progressing key clinical trials of its psychedelic therapies and strengthening its leadership team. The company secured $6 million in funding and launched a world-first trial targeting Binge Eating Disorder.
Ada Torres
Ada Torres
29 Aug 2025
Mesoblast Limited has reported its FY2025 results, highlighting the FDA approval and US commercial launch of Ryoncil, its first mesenchymal stromal cell therapy, alongside a $102.1 million net loss and $161.6 million in cash reserves.
Ada Torres
Ada Torres
29 Aug 2025
Island Pharmaceuticals reported a $3.92 million loss for FY2025 despite an 86% increase in income, with no dividends declared.
Ada Torres
Ada Torres
29 Aug 2025
BTC Health Limited reported a robust 25% revenue increase in FY25, driven by strategic contract wins and expanded product offerings across critical medical sectors. The company’s positive EBITDA and new partnerships position it well for continued growth in FY26.
Ada Torres
Ada Torres
28 Aug 2025
BTC Health reports a strong FY25 with a $4 million statutory profit, boosted by a $5 million contract and strategic acquisition. The company eyes further growth in FY26 with new product launches and expanded market reach.
Ada Torres
Ada Torres
28 Aug 2025
BTC Health Limited reported a remarkable 277% increase in profit after tax to nearly $4 million for FY25, driven by significant fair value gains on its healthcare investments and key contract wins.
Ada Torres
Ada Torres
28 Aug 2025
Algorae Pharmaceuticals reported a 62% reduction in net loss for FY2025, driven by R&D tax credits and cost efficiencies, while making significant strides in its AI drug discovery platform and therapeutic candidates.
Ada Torres
Ada Torres
28 Aug 2025
Avecho Biotechnology reported a 79% revenue increase driven by a $4.8 million upfront licensing fee from Sandoz, yet its half-year loss grew 23% as R&D and administrative costs rose. The company advances its Phase III CBD insomnia trial while pursuing further international licensing.
Ada Torres
Ada Torres
28 Aug 2025
Syntara Limited reported a significantly reduced loss for FY2025, driven by clinical progress and capital raises, while advancing its lead drug amsulostat with FDA Fast Track designation. The company also navigates ongoing payment disputes following the sale of its mannitol respiratory business.
Ada Torres
Ada Torres
28 Aug 2025
Clarity Pharmaceuticals reported a $64.3 million loss for FY2025 alongside significant clinical progress and a $203.6 million placement to fund its radiopharmaceutical pipeline expansion.
Ada Torres
Ada Torres
28 Aug 2025
Clinuvel Pharmaceuticals has reported a robust financial year ending June 2025, marked by solid revenue growth and sustained profitability, while advancing its clinical pipeline and maintaining a strong balance sheet.
Ada Torres
Ada Torres
28 Aug 2025
Clinuvel Pharmaceuticals has reported its ninth consecutive year of revenue and profit growth, driven by strong sales of SCENESSE® and strategic investment in vitiligo clinical trials. The company also declared its eighth consecutive dividend, underscoring financial resilience.
Ada Torres
Ada Torres
28 Aug 2025